Related Experiment Video

Updated: Sep 23, 2025

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.0K

Multi-inflammatory Index as a Novel Mortality Predictor in Critically Ill COVID-19 Patients

Hasan Tahsin Gozdas1, Seyit Ali Kayis2, Tugce Damarsoy1

  • 1Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, 52942Abant Izzet Baysal University, Bolu, Turkey.

Journal of Intensive Care Medicine
|May 11, 2022
PubMed

Insights

The Multi-Inflammatory Index (MII) effectively predicts mortality in COVID-19 patients within the ICU. This novel index, combining Neutrophil to Lymphocyte Ratio (NLR) and C-reactive protein (CRP), offers a practical tool for assessing patient outcomes.

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Biomarkers

Background:

  • Systemic inflammation significantly impacts COVID-19 pathogenesis and mortality.
  • The Multi-Inflammatory Index (MII) is a novel indicator of systemic inflammation.
  • Predicting mortality in intensive care unit (ICU) patients with COVID-19 is crucial.

Purpose of the Study:

  • To investigate the association between the Multi-Inflammatory Index (MII) and in-hospital mortality in COVID-19 patients admitted to the ICU.
  • To evaluate MII's efficacy as a predictor of mortality compared to other inflammatory markers.

Main Methods:

  • Retrospective analysis of medical records for 348 COVID-19 patients admitted to the ICU between April 2020 and October 2021.
  • Classification of patients into survivor and non-survivor groups based on mortality status.
  • Comparison of various inflammatory parameters and assessment of their predictive value for mortality using logistic regression.

Main Results:

  • The study included 348 patients, with 24.7% survivors and 75.3% non-survivors.
  • The non-survivor group had a significantly higher median age (76 vs. 65.5 years, P < .001).
  • MII demonstrated the highest efficacy in predicting mortality (OR: 0.999; 95% CI: 0.9991-0.9998; P = .003) among all inflammatory parameters analyzed.

Conclusions:

  • The Multi-Inflammatory Index (MII), a combination of Neutrophil to Lymphocyte Ratio (NLR) and C-reactive protein (CRP), is a valuable and practical biomarker.
  • MII can aid in predicting mortality for COVID-19 patients managed in the ICU.
  • This simple index offers a promising tool for risk stratification in critically ill COVID-19 patients.
Abstract

Keywords:
coronavirus disease 2019intensive care unitmortalitymulti-inflammatory index

More Related Videos

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics11:02

Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics

Published on: November 29, 2024

670
Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury14:48

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury

Published on: March 21, 2021

5.2K

Related Concept Videos

Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
5.2K
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
46
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
24
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
34
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
35